

# Topical Paromomycin with or without Gentamicin for C

New England Journal of Medicine

368, 524-532

DOI: [10.1056/nejmoa1202657](https://doi.org/10.1056/nejmoa1202657)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Therapeutic Options for Old World Cutaneous Leishmaniasis and New World Cutaneous and Mucocutaneous Leishmaniasis. <i>Drugs</i> , 2013, 73, 1889-1920.	4.9	108
3	Aminoglycoside therapy in infectious diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1585-1597.	0.9	65
4	Travelers With Cutaneous Leishmaniasis Cured Without Systemic Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 370-380.	2.9	52
5	Identification of the molecular attributes required for aminoglycoside activity against <i>Leishmania</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13333-13338.	3.3	31
6	Aminoglycosides. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 516-525.	1.3	65
7	Editorial Commentary: Local Treatments for Cutaneous Leishmaniasis. <i>Clinical Infectious Diseases</i> , 2013, 57, 381-383.	2.9	7
8	Clinical and Epidemiologic Profile of Cutaneous Leishmaniasis in Colombian Children: Considerations for Local Treatment. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 359-364.	0.6	22
10	Pharmacokinetics and Absorption of Paromomycin and Gentamicin from Topical Creams Used To Treat Cutaneous Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4809-4815.	1.4	19
11	In vitro Interaction between SURFACENÁ® and Surfactant Protein A against <i>Leishmania amazonensis</i> . <i>Chemotherapy</i> , 2013, 59, 247-250.	0.8	0
13	Brothers in arms. <i>EMBO Reports</i> , 2013, 14, 866-870.	2.0	0
14	Miscellaneous Antibacterial Drugs. <i>Side Effects of Drugs Annual</i> , 2014, , 363-380.	0.6	0
15	Parasitic diseases in travelers: a focus on therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 497-521.	2.0	5
16	In silico work flow for scaffold hopping in <i>Leishmania</i> . <i>BMC Research Notes</i> , 2014, 7, 802.	0.6	9
17	Leishmanioses cutanéas. , 2014, , 219-227.		0
18	Parasite Load Decrease during Application of a Safe and Easily Applied Antileishmanial Aminoglycoside Cream. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2749.	1.3	12
19	Species-Directed Therapy for Leishmaniasis in Returning Travellers: A Comprehensive Guide. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2832.	1.3	74
20	Easy Identification of <i>Leishmania</i> Species by Mass Spectrometry. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2841.	1.3	34
21	Leishmaniasis in the Middle East: Incidence and Epidemiology. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3208.	1.3	137

#	ARTICLE	IF	CITATIONS
22	Rapid Healing of Cutaneous Leishmaniasis by High-Frequency Electrocauterization and Hydrogel Wound Care with or without DAC N-055: A Randomized Controlled Phase IIa Trial in Kabul. PLoS Neglected Tropical Diseases, 2014, 8, e2694.	1.3	27
23	Topical Paromomycin and Gentamicin for New World Cutaneous Leishmaniasis in Panama. American Journal of Tropical Medicine and Hygiene, 2014, 90, 1191-1191.	0.6	8
24	Number needed to treat for time-to-event data with competing risks. Statistics in Medicine, 2014, 33, 181-192.	0.8	16
26	Erythematous Nodule of the Left Eyebrow in a 14-Year-Old Boy. JAMA Dermatology, 2014, 150, 201.	2.0	1
27	Drug repurposing and human parasitic protozoan diseases. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 95-111.	1.4	286
28	Update on new medicinal applications of gentamicin: Evidence-based review. Journal of the Formosan Medical Association, 2014, 113, 72-82.	0.8	55
29	Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis. Expert Opinion on Drug Delivery, 2014, 11, 579-597.	2.4	38
30	Leishmaniasis in Maghreb: An endemic neglected disease. Acta Tropica, 2014, 132, 80-93.	0.9	32
31	Leishmaniasis: clinical syndromes and treatment. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 7-14.	0.2	308
32	Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chemical Reviews, 2014, 114, 11305-11347.	23.0	274
33	LeishMan Recommendations for Treatment of Cutaneous and Mucosal Leishmaniasis in Travelers, 2014. Journal of Travel Medicine, 2014, 21, 116-129.	1.4	110
34	New trends in the use of aminoglycosides. MedChemComm, 2014, 5, 1075-1091.	3.5	68
35	Neglected Tropical Diseases - Middle East and North Africa. Neglected Tropical Diseases, 2014, , .	0.4	7
36	Pathogenesis of Leishmaniasis. , 2014, , .		2
38	Leishmania tropica in children: A retrospective study. Journal of the American Academy of Dermatology, 2014, 71, 271-277.	0.6	36
39	Treatment Modalities for Cutaneous and Visceral Leishmaniasis. , 2014, , 77-90.		0
40	Ablative fractional laser resurfacing with topical paromomycin as adjunctive treatment for a recalcitrant cutaneous leishmaniasis wound. Lasers in Surgery and Medicine, 2015, 47, 788-791.	1.1	10
41	Nanoemulsions containing a synthetic chalcone as an alternative for treating cutaneous leishmaniasis: optimization using a full factorial design. International Journal of Nanomedicine, 2015, 10, 5529.	3.3	36

#	ARTICLE	IF	CITATIONS
42	Spatio-temporal Genetic Structuring of <i>Leishmania major</i> in Tunisia by Microsatellite Analysis. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004017.	1.3	8
43	Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB). <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004041.	1.3	20
44	Aminoglycosides. , 2015, , 310-321.e7.		9
45	Cutaneous Leishmaniasis in Travellers: a Focus on Epidemiology and Treatment in 2015. <i>Current Infectious Disease Reports</i> , 2015, 17, 489.	1.3	24
46	Drugs for Protozoal Infections Other Than Malaria. , 2015, , 510-518.e3.		4
47	Structural basis for selective targeting of leishmanial ribosomes: aminoglycoside derivatives as promising therapeutics. <i>Nucleic Acids Research</i> , 2015, 43, 8601-8613.	6.5	28
48	Cutaneous and mucocutaneous leishmaniasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 911-926.	0.6	143
49	Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 52-62.	0.8	39
50	Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an <i>Ex Vivo</i> Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6463-6470.	1.4	20
51	InÂvitro and inÂvivo antileishmanial effects of aloe-emodin on <i>Leishmania major</i> . <i>Journal of Traditional and Complementary Medicine</i> , 2015, 5, 96-99.	1.5	36
52	Cutaneous leishmaniasis - treatment options in children. <i>British Journal of Dermatology</i> , 2015, 172, 844-845.	1.4	1
53	Assessment of Î²-lapachone loaded in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis in <i>L. major</i> infected BALB/c mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 2003-2012.	1.7	49
54	Conventional formulations and emerging delivery systems for the topical treatment of Cutaneous Leishmaniasis. <i>Therapeutic Delivery</i> , 2015, 6, 101-103.	1.2	8
55	Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic. <i>British Journal of Dermatology</i> , 2015, 172, 861-866.	1.4	7
56	Unexpected co-detection of promastigote and amastigote <i>Leishmania</i> forms in a human cutaneous lesion: implications for leishmaniasis physiopathology and treatment. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 18-20.	0.8	0
57	An update on pharmacotherapy for leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 237-252.	0.9	213
58	Nanoparticles in the Topical Treatment of Cutaneous Leishmaniasis. , 2016, , 135-155.		4
59	Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against <i>Leishmania</i> in mice model. <i>Parasite Immunology</i> , 2016, 38, 599-608.	0.7	59

#	ARTICLE	IF	CITATIONS
60	Essential oils: in vitro activity against <i>Leishmania amazonensis</i> , cytotoxicity and chemical composition. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 444.	3.7	52
61	Treatment Options for Leishmaniasis. <i>Current Clinical Microbiology Reports</i> , 2016, 3, 198-203.	1.8	0
62	DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis. <i>Scientific Reports</i> , 2016, 6, 38330.	1.6	34
63	Topical Treatment of <i>Leishmania tropica</i> Infection Using (α)-β-Bisabolol Ointment in a Hamster Model: Effectiveness and Safety Assessment. <i>Journal of Natural Products</i> , 2016, 79, 2403-2407.	1.5	16
64	Leishmaniosis cutánea. <i>EMC - Dermatología</i> , 2016, 50, 1-12.	0.1	3
66	Antibiotic and Antifungal Therapies in Dermatology. , 2016, , .		0
67	Monitoring the response of patients with cutaneous leishmaniasis to treatment with pentamidine isethionate by quantitative real-time PCR, and identification of <i>Leishmania</i> parasites not responding to therapy. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 610-615.	0.6	8
68	Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 793-794.	0.6	8
69	Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). <i>Clinical Infectious Diseases</i> , 2016, 63, e202-e264.	2.9	235
70	Structural modifications of the neomycin class of aminoglycosides. <i>MedChemComm</i> , 2016, 7, 1499-1534.	3.5	14
71	Aminoglycosides: An Overview. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a027029.	2.9	590
72	Drug permeation and barrier damage in <i>Leishmania</i> -infected mouse skin. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1578-1585.	1.3	42
73	Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against <i>Leishmania tropica</i> infection in BALB/c mice model. <i>Applied Microbiology and Biotechnology</i> , 2016, 100, 7051-7060.	1.7	35
74	Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries. <i>Acta Tropica</i> , 2016, 155, 113-123.	0.9	79
75	Development and evaluation of zinc phthalocyanine nanoemulsions for use in photodynamic therapy for <i>Leishmania</i> spp. <i>Nanotechnology</i> , 2017, 28, 065101.	1.3	33
76	In Vitro Sensitivity of Cutaneous <i>Leishmania</i> Promastigote Isolates Circulating in French Guiana to a Set of Drugs. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 16-0373.	0.6	10
77	Insights from spectroscopic and in-silico techniques for the exploitation of biomolecular interactions between Human serum albumin and Paromomycin. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 157, 242-253.	2.5	15
78	Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a systematic review. <i>Parasitology</i> , 2017, 144, 995-1004.	0.7	54

#	ARTICLE	IF	CITATIONS
79	Nuclear DNA replication and repair in parasites of the genus <i>Leishmania</i> : Exploiting differences to develop innovative therapeutic approaches. <i>Critical Reviews in Microbiology</i> , 2017, 43, 156-177.	2.7	16
80	Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 24-45.	0.6	191
81	Synthetic analogs of an <i>Entamoeba histolytica</i> glycolipid designed to combat intracellular <i>Leishmania</i> infection. <i>Scientific Reports</i> , 2017, 7, 9472.	1.6	7
82	Interventions for Old World cutaneous leishmaniasis. <i>The Cochrane Library</i> , 2017, 12, CD005067.	1.5	66
83	Interventions for Old World cutaneous leishmaniasis. <i>The Cochrane Library</i> , 2017, 11, CD005067.	1.5	8
84	Lipid-core nanocapsules increase the oral efficacy of quercetin in cutaneous leishmaniasis. <i>Parasitology</i> , 2017, 144, 1769-1774.	0.7	30
85	Cutaneous Leishmaniasis Induces a Transmissible Dysbiotic Skin Microbiota that Promotes Skin Inflammation. <i>Cell Host and Microbe</i> , 2017, 22, 13-24.e4.	5.1	82
86	Blood and Tissue Protozoa. , 2017, , 1751-1762.e1.		0
87	Antiparasitic Agents. , 2017, , 1345-1372.e2.		15
88	Cutaneous Leishmaniasis in a Saudi Arabian Soldier Stationed in the United States. <i>Military Medicine</i> , 2017, 182, e1953-e1956.	0.4	1
89	A Synthetic Strategy for Conjugation of Paromomycin to Cell-Penetrating Tat(48-60) for Delivery and Visualization into <i>Leishmania</i> Parasites. <i>International Journal of Peptides</i> , 2017, 2017, 1-7.	0.7	10
90	Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006094.	1.3	50
91	Antileishmanial and antitrypanosomal drug identification. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 613-620.	1.1	5
92	Improved drug loading via spray drying of a chalcone implant for local treatment of cutaneous leishmaniasis. <i>Drug Development and Industrial Pharmacy</i> , 2018, 44, 1473-1480.	0.9	7
93	<i>Leishmania</i> Species (Leishmaniasis). , 2018, , 1323-1334.e3.		1
94	Treatment of Tegumentary Forms of Leishmaniasis. , 2018, , 191-225.		1
95	Topical Paromomycin for treating solitary mucosal leishmaniasis. <i>International Journal of Dermatology</i> , 2018, 57, 721-723.	0.5	1
96	The Leishmaniasis: Old Neglected Tropical Diseases. , 2018, , .		35

#	ARTICLE	IF	CITATIONS
97	Leishmaniasis and various immunotherapeutic approaches. <i>Parasitology</i> , 2018, 145, 497-507.	0.7	58
98	Chemotherapy of leishmaniasis: present challenges. <i>Parasitology</i> , 2018, 145, 464-480.	0.7	153
99	Rapidly progressing facial leishmaniasis: effective treatment with liposomal amphotericin B and a review of the management of Old World cutaneous leishmaniasis. <i>Paediatrics and International Child Health</i> , 2018, 38, 158-161.	0.3	5
100	<i>Leishmania</i> and other intracellular pathogens: selectivity, drug distribution and PK&#x2013;PD. <i>Parasitology</i> , 2018, 145, 237-247.	0.7	15
101	Nanomedicines for Cutaneous Leishmaniasis. , 0, , .		3
102	Meglumine antimoniate-induced DRESS: original case with a positive skin test. <i>Acta Parasitologica</i> , 2018, 63, 845-847.	0.4	2
103	Cutaneous Leishmaniasis in an American Adolescent Returning From Israel. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, e178-e181.	0.6	1
104	In vitro screening of known drugs identified by scaffold hopping techniques shows promising leishmanicidal activity for suramin and netilmicin. <i>BMC Research Notes</i> , 2018, 11, 319.	0.6	11
105	Leishmaniasis. <i>Lancet, The</i> , 2018, 392, 951-970.	6.3	1,264
106	Intralesional sodium stibogluconate under inhaled anesthesia for the treatment of cutaneous leishmaniasis in children: A retrospective cohort. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1013-1015.	0.6	2
107	Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 11, 148-155.	1.4	13
108	Investigation of unknown impurities of paromomycin in a 15% topical cream by liquid chromatography combined with mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2019, 33, 1660-1669.	0.7	1
110	Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 11, 156-165.	1.4	31
111	Cutaneous Leishmaniasis. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 101-117.	1.9	76
112	Allergic contact dermatitis caused by paromomycin. <i>Contact Dermatitis</i> , 2019, 81, 393-394.	0.8	5
113	Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 11, 106-117.	1.4	58
114	Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 595-612.	1.5	3
115	Topically Applied Chitosan-Coated Poly(isobutylcyanoacrylate) Nanoparticles Are Active Against Cutaneous Leishmaniasis by Accelerating Lesion Healing and Reducing the Parasitic Load. <i>ACS Applied Bio Materials</i> , 2019, 2, 2573-2586.	2.3	16

#	ARTICLE	IF	CITATIONS
116	Development of topical liposomes containing miltefosine for the treatment of <i>Leishmania major</i> infection in susceptible BALB/c mice. <i>Acta Tropica</i> , 2019, 196, 142-149.	0.9	35
117	Current and emerging medications for the treatment of leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1251-1265.	0.9	114
118	Old World cutaneous leishmaniasis treatment response varies depending on parasite species, geographical location and development of secondary infection. <i>Parasites and Vectors</i> , 2019, 12, 195.	1.0	15
119	Topical paromomycin for New World cutaneous leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007253.	1.3	48
120	Repurposed Molecules: A New Hope in Tackling Neglected Infectious Diseases. , 2019, , 119-160.		9
121	Drug repurposing for antimicrobial discovery. <i>Nature Microbiology</i> , 2019, 4, 565-577.	5.9	217
122	Leishmaniasis and Chagas Disease “ Neglected Tropical Diseases: Treatment Updates. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 174-177.	1.0	36
124	Antiparasitics from Microorganisms. <i>Environmental Chemistry for A Sustainable World</i> , 2019, , 27-47.	0.3	0
125	Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis. <i>Pharmaceutics</i> , 2019, 11, 613.	2.0	11
126	Evaluation of Skin Permeation and Retention of Topical Dapsone in Murine Cutaneous Leishmaniasis Lesions. <i>Pharmaceutics</i> , 2019, 11, 607.	2.0	12
127	Microneedle-Based Delivery of Amphotericin B for Treatment of Cutaneous Leishmaniasis. <i>Biomedical Microdevices</i> , 2019, 21, 8.	1.4	18
128	Topical 15% Paromomycin-Aquaphilic for Bolivian <i>Leishmania braziliensis</i> Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 844-849.	2.9	20
130	Identification of Phenylphthalazinones as a New Class of <i>Leishmania infantum</i> Inhibitors. <i>ChemMedChem</i> , 2020, 15, 219-227.	1.6	4
131	Cutaneous leishmaniasis in refugees from Syria: complex cases in Berlin 2015–2020. <i>Journal of Travel Medicine</i> , 2020, 27, .	1.4	10
132	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. <i>Cellular Signalling</i> , 2020, 74, 109721.	1.7	105
133	Derivatization-free determination of aminoglycosides by CZE–UV in pharmaceutical formulations. <i>Electrophoresis</i> , 2020, 41, 1576-1583.	1.3	5
134	Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis. <i>Microorganisms</i> , 2020, 8, 1803.	1.6	4
135	Trypanosomatid-Caused Conditions: State of the Art of Therapeutics and Potential Applications of Lipid-Based Nanocarriers. <i>Frontiers in Chemistry</i> , 2020, 8, 601151.	1.8	9

#	ARTICLE	IF	CITATIONS
136	Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?. <i>Microorganisms</i> , 2020, 8, 1069.	1.6	16
137	Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases. <i>ACS Infectious Diseases</i> , 2020, 6, 2647-2660.	1.8	21
138	A review of current treatments strategies based on paromomycin for leishmaniasis. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 57, 101664.	1.4	21
139	Content for self-care app for patients with cutaneous leishmaniasis: Designing a mobile-based self-care app for patients with cutaneous leishmaniasis. <i>Health Policy and Technology</i> , 2021, 10, 87-94.	1.3	2
140	Chemogenomics and bioinformatics approaches for prioritizing kinases as drug targets for neglected tropical diseases. <i>Advances in Protein Chemistry and Structural Biology</i> , 2021, 124, 187-223.	1.0	2
141	Topical Treatment of Cutaneous Leishmaniasis: A Case Treated with A Glucantime-Based Lotion Experienced in Ecuador and A Mini Review. , 2021, 01, .		0
142	Walter Reed Army Institute of Research (WRAIR): Fifty Years of Achievements That Impact Science and Society. <i>Military Medicine</i> , 2021, 186, 72-77.	0.4	4
143	Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009099.	1.3	32
144	Susceptibility to paromomycin in clinical isolates and reference strains of <i>Leishmania</i> species responsible for tegumentary leishmaniasis in Brazil. <i>Acta Tropica</i> , 2021, 215, 105806.	0.9	7
145	Comparison between cutaneous leishmaniasis patients with facial and non-facial lesions. <i>International Journal of Dermatology</i> , 2021, 60, 1109-1113.	0.5	1
146	Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis. <i>Pharmaceutics</i> , 2021, 13, 516.	2.0	11
147	Cutaneous and Mucocutaneous Leishmaniasis. <i>Actas Dermo-sifiligráficas</i> , 2021, , .	0.2	13
148	Miltefosine for the treatment of cutaneous leishmaniasisâ€”A pilot study from Ethiopia. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009460.	1.3	13
149	Leishmaniasis cutánea y mucocutánea. <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 601-618.	0.2	38
150	Comparative assessment of interventions for treating cutaneous leishmaniasis: A network meta-analysis of randomized clinical trials.. <i>Acta Tropica</i> , 2021, 220, 105944.	0.9	2
152	Broad-spectrum therapeutics: A new antimicrobial class. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100011.	1.7	7
153	Aminoglycosides: Mechanisms of Action and Resistance. , 2017, , 213-229.		8
154	Cutaneous Leishmaniasis in Middle East and North Africa. <i>Neglected Tropical Diseases</i> , 2014, , 117-139.	0.4	4

#	ARTICLE	IF	CITATIONS
155	Spatiotemporal and molecular epidemiology of cutaneous leishmaniasis in Libya. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005873.	1.3	16
156	Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. <i>PLoS ONE</i> , 2017, 12, e0184777.	1.1	66
157	Psycho-social impacts, experiences and perspectives of patients with Cutaneous Leishmaniasis regarding treatment options and case management: An exploratory qualitative study in Tunisia. <i>PLoS ONE</i> , 2020, 15, e0242494.	1.1	16
158	Cutaneous Leishmaniasis in Erbil Governorate: Clinical manifestations and disease course. <i>Medical Journal of the Islamic Republic of Iran</i> , 2018, 32, 411-413.	0.9	2
159	In Silico Chemogenomics Drug Repositioning Strategies for Neglected Tropical Diseases. <i>Current Medicinal Chemistry</i> , 2019, 26, 4355-4379.	1.2	24
160	Drug Repurposing for the Treatment of Staphylococcal Infections. <i>Current Pharmaceutical Design</i> , 2015, 21, 2089-2100.	0.9	40
161	Leishmaniasis: History, Evolution of Treatment and the Need for New Drugs. <i>Current Biotechnology</i> , 2015, 3, 279-288.	0.2	3
162	Liposomal Amphotericin B Treatment and the Leishmaniases. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 727-728.	0.6	7
163	Clinical diversity and treatment results in Tegumentary Leishmaniasis: A European clinical report in 459 patients. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009863.	1.3	12
164	New therapy for cutaneous leishmaniasis. <i>Nature Middle East</i> , 0, , .	0.0	0
167	Cutaneous Leishmaniasis. , 2016, , 291-338.		1
168	Infectious Diseases: Leishmaniasis. , 2017, , 249-252.		0
169	Editorial: The Value of New Knowledge. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00322.	0.6	2
170	Caesalpinia spinosa (Molina) Kuntze: una nueva promesa para el tratamiento tpico de la leishmaniasis cutnea. <i>Revista De La Academia Colombiana De Ciencias Exactas, Fısicas Y Naturales</i> , 2020, 44, 915-936.	0.0	2
171	An overview of the treatment of cutaneous leishmaniasis. <i>Faculty Reviews</i> , 2020, 9, 28.	1.7	19
172	A pilot and open trial to evaluate topical Bacterial Cellulose bio-curatives in the treatment of cutaneous leishmaniasis caused by <i>L. braziliensis</i> . <i>Acta Tropica</i> , 2022, 225, 106192.	0.9	2
173	Development of a biocompatible polymeric chitosan system for the release of compounds with leishmanicidal activity. <i>Materials and Design</i> , 2021, 212, 110232.	3.3	2
174	Apoptotic Effect of Morphine, Imiquimod and Nalmefene on Promastigote, Infected and Uninfected Macrophages with Amastigote of by Flow Cytometry. <i>Iranian Journal of Pharmaceutical Research</i> , 2018, 17, 986-994.	0.3	6

#	ARTICLE	IF	CITATIONS
175	Effectiveness of Paromomycin on Cutaneous Leishmaniasis in Iran: A Systematic Review and Meta-Analysis. <i>Iranian Journal of Medical Sciences</i> , 2019, 44, 185-195.	0.3	3
176	A profile of research on the parasitic trypanosomatids and the diseases they cause. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010040.	1.3	22
177	Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2022, 11, 695-711.	1.8	20
178	Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021. <i>Expert Opinion on Therapeutic Patents</i> , 2022, 32, 591-604.	2.4	14
179	Tratamiento Combinado en Leishmaniasis Cutánea con Falla Terapéutica. <i>Gaceta Medica Boliviana</i> , 2021, 44, 260-264.	0.0	0
180	Treatment of Cutaneous Leishmaniasis in a Nonendemic Country: A Case Series of Children in Australia. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, e177-e181.	1.1	0
181	Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis. <i>Frontiers in Tropical Diseases</i> , 2022, 3, .	0.5	17
183	Treatment outcome of imported cutaneous leishmaniasis among travelers and migrants infected with <i>Leishmania major</i> and <i>Leishmania tropica</i> : a retrospective study in European centers 2013 to 2019. <i>International Journal of Infectious Diseases</i> , 2022, 122, 375-381.	1.5	1
184	Topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis caused by <i>Leishmania major</i> : a double-blind, randomized, placebo-controlled, pilot study. <i>International Journal of Dermatology</i> , 2023, 62, 40-47.	0.5	4
185	Immunological detection using immune cytokines for human cutaneous leishmaniasis in Al-Najaf Al-Ashraf governorate. <i>International Journal of Health Sciences</i> , 0, , 8841-8859.	0.0	0
186	<i>Leishmania</i> Species (Leishmaniasis). , 2023, , 1354-1364.e4.		1
187	In Vivo Safety and Efficacy of Chalcone-Loaded Microparticles with Modified Polymeric Matrix against Cutaneous Leishmaniasis. <i>Pharmaceutics</i> , 2023, 15, 51.	2.0	3
188	Leishmaniasis: Biology, clinical diagnosis, and treatment. , 2023, , 407-415.		1